Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
RECRUITING
NCT07222709
PHASE1
A Study to Assess the Adverse Events and How Oral ABBV-1042 Moves Through the Body of Healthy Adult Participants
Sponsor: AbbVie
View on ClinicalTrials.gov
Summary
This study will assess the adverse events, tolerability, and how oral ascending doses of ABBV-1042 moves through the body of healthy adult participants.
Official title: A Phase 1, Double-blind, Placebo-controlled, First-in-human Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of ABBV-1042 in Healthy Subjects
Key Details
Gender
All
Age Range
18 Years - 55 Years
Study Type
INTERVENTIONAL
Enrollment
48
Start Date
2025-10-27
Completion Date
2026-05
Last Updated
2025-10-30
Healthy Volunteers
Yes
Conditions
Interventions
DRUG
ABBV-1042
Oral Solution
DRUG
Placebo
Oral Solution
Locations (1)
Acpru /Id# 279405
Grayslake, Illinois, United States